TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06682273

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thread-embedding acupuncture
Description: Thread-embedding acupuncture is performed every week for 4 weeks, using a single Polydioxaone thread inserted into acupoints on the body through the needle. After the thread is inserted, the needle will be immediately withdrawn.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Thread-embedding acupuncture
Description: Thread-embedding acupuncture is performed every week for 4 weeks, using a single Polydioxaone thread inserted into acupoints on the body through the needle. After the thread is inserted, the needle will be immediately withdrawn.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Auricular acupuncture
Description: Auricular acupuncture is conducted weekly for 4 weeks using patches, each with a square shape and a side length of 10 mm, along with a sterilized needle measuring 0.25 x 1.3 mm inserted into therapeutic points on the ear. The patches with the needle will remain in place for one week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auricular acupuncture
Description: Auricular acupuncture is conducted weekly for 4 weeks using patches, each with a square shape and a side length of 10 mm, along with a sterilized needle measuring 0.25 x 1.3 mm inserted into therapeutic points on the ear. The patches with the needle will remain in place for one week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sham thread-embedding acupuncture
Description: Sham thread-embedding acupuncture is performed every week for 4 weeks, using the needle without thread inserted into acupoints on the body. After insertion, the needle will be immediately withdrawn, and no thread will be left in the body.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham thread-embedding acupuncture
Description: Sham thread-embedding acupuncture is performed every week for 4 weeks, using the needle without thread inserted into acupoints on the body. After insertion, the needle will be immediately withdrawn, and no thread will be left in the body.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham auricular acupuncture
Description: Sham auricular acupuncture is conducted weekly for 4 weeks using patches, each with a square shape and a side length of 10 mm, along with a sterilized needle measuring 0.25 x 1.3 mm inserted into non-therapeutic points on the ear. The patches with the needle will remain in place for one week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sham auricular acupuncture
Description: Sham auricular acupuncture is conducted weekly for 4 weeks using patches, each with a square shape and a side length of 10 mm, along with a sterilized needle measuring 0.25 x 1.3 mm inserted into non-therapeutic points on the ear. The patches with the needle will remain in place for one week.
Study: NCT06682000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWC202404, DWC202314
Description: - 2 tablet, Oral, Once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DWC202404, DWC202314P
Description: - 2 tablet, Oral, Once a day
Study: NCT06158100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax will be given orally (PO) at the assigned doses of 50 or 100 mg once daily for 7, 14 or 21 days starting at day 1 of each 28-day cycle, for up to 12 cycles.
Study: NCT06690723

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin (Forxiga)
Description: Dapagliflozin plus lifestyle modification

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 ( Colecalciferol)
Description: Vitamin D3 plus lifestyle modification
Study: NCT03149211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UB-421
Description: Subjects will receive 13 doses of the UB-421 by intravenous infusion at 25 mg/kg bi-weekly (Cohort 2, 26 weeks).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: current standard HAART treatment
Description: Subjects will receive current standard HAART treatment as the active control group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: current standard HAART treatment
Description: Subjects will receive current standard HAART treatment as the active control group.
Study: NCT06690723

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 plus Dapagliflozin
Description: Vitamin D3 plus Dapagliflozin plus lifestyle modification

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle modification
Description: Lifestyle modification alone
Study: NCT06687538

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile application
Description: The content of the mobile application training to be developed for patients who will undergo transurethral prostate resection will consist of 3 modules including preoperative, postoperative and discharge training process.
Study: NCT06689943

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tylenol
Description: Tylenol for children

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tylenol
Description: Tylenol for children
Study: NCT06689761

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ColCT
Description: Dietary Supplement: Collagen Participants ingest 15 grams of specific collagen peptides daily

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ColET
Description: Dietary Supplement: Collagen Participants ingest 15 grams of specific collagen peptides daily

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: PlaCT
Description: Dietary Supplement: Placebo. Participants ingest 15 grams of placebo daily

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: PlaET
Description: Dietary Supplement: Placebo. Participants ingest 15 grams of placebo daily
Study: NCT06690554

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education Group
Description: Women will be given a five-day training in line with the health promotion model.~Information will be provided to women who apply to the hospital. Written consent documents will be obtained from women who agree to participate in the study.~Women assigned to the intervention group will attend classes in groups of 8-10. Women will be given a 60-minute training once a day for five days. The total training duration is five hours. Scales will be applied to women who complete the training at the end of the fifth day.~Women who have completed the training will be contacted by phone at the end of the first and second months, reminded of health promotion behaviors and their questions will be answered and follow-ups will be carried out.~At the end of the third month, women who have received training will be invited to the institution and the Fertility Awareness, Preconceptional Knowledge and Attitude will be filled out face-to-face for the final test.
Study: NCT06690944

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive Neuromuscular Facilitation
Description: The following basic principles and procedures were emphasized when applying the techniques: manual contact, resistance, approximation, verbal commands, and therapist's body mechanics. During stages 1 and 2 of the intervention, the amount of PNF optimal resistance used was necessary to maintain a stable and safe position, with good body alignment, in a manner that produced coordinated movements to generate appropriate motor learning.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical exercise without proprioceptive neuromuscular facilitation control group
Description: The physical exercise without proprioceptive neuromuscular facilitation control group (CG) intervention consisted of the same activities carried out in the proprioceptive neuromuscular facilitation (PNF) group during Stages 1 and 2, during the same amount of minutes, sessions, and weeks; however, CG intervention did not include specific techniques and basic principles (i.e. approximation and optimal resistance) and procedures of the PNF concept. The activities were instructed and supervised by a trained professional through verbal command. The professional was at stand-by assistant position to prevent accidents.
Study: NCT06691919

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Direct Endoscopic Necrosectomy with Powered Endoscopic Debridement
Description: Patients will first undergo endoscopic ultrasound-guided cystgastrostomy using an electrocautery-enhanced lumen apposing metallic stent to gain access to the necrosum. Direct Endoscopic Necrosectomy will be performed using the EndoRotor® NecroMax 6.0 PED Catheter which has an outer diameter of 5.1 mm and is compatible with endoscopes that have a working channel of ≥6.0 mm.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transgastric Surgical Necrosectomy
Description: Patients randomized to the surgical arm will undergo open or minimally invasive (laparoscopic) transgastric SN with the aim of creating an ample size cystgastrostomy to perform a complete debridement. In either approach, the peritoneal cavity is entered to identify the stomach through which an anterior gastrotomy is made. The retrogastric necrosum is identified either using a finder needle or ultrasound and accessed through a posterior cystgastrostomy. Transgastric SN is then manually performed, and any cyst fluid fully evacuated. The anterior gastrotomy is then closed allowing any residual necrosis or pancreatic enzyme to efflux into the stomach and enter the upper GI tract. As with endoscopy, patients with retrogastric collections are observed for a sufficient period to ensure full maturation of the necrosum.
Study: NCT06696053

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transversal therapeutic education
Description: Additional patient consultation for therapeutic education with nurses.
Study: NCT06694129

Intervention type: DRUG
Intervention: Entrectinib
Description: Patients in each cohort were treated with Entrectinib.

Intervention type: DRUG
Intervention: Entrectinib
Description: Patients in each cohort were treated with Entrectinib.

Intervention type: DRUG
Intervention: Entrectinib
Description: Patients in each cohort were treated with Entrectinib.
Study: NCT06687902

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Digital breast tomosynthesis
Description: In digital breast tomosynthesis (DBT), images are acquired using a specialized X-ray tube that moves in an arc around the breast. This technique captures multiple low-dose images from various angles, typically within a 15° to 60° range. These images are then reconstructed into 1-mm slices to create a 3D representation of the breast, allowing for detailed layer-by-layer evaluation. The number of images acquired varies depending on the size of the breast and the specifications of the equipment but generally ranges from 10 to 25 projections, captured within a few seconds.
Study: NCT06689670

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Needle based delivery of INT001 into liver tumors under real-time image guidance
Description: Using ultrasound or CT imaging, the liver tumor is located. Under local anesthesia or, if necessary, intravenous sedation, the needle is inserted through the skin and the needle tip is brought to the center of the liver tumor using image guidance. 1-2 ml of the INT-001 is injected. The needle is removed and a bandaid is applied to the skin entry site. Right after, or as soon as MRI becomes available, MRI is performed to show that the entire tumor has been treated.
Study: NCT06688682

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PRP joint injection combined with acupoint injection
Description: PRP acupoint injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PRP joint injection combined with acupoint injection
Description: PRP acupoint injection
Study: NCT06689748

Intervention type: OTHER
Intervention: Delphi procedure
Description: The study involves generating consensus statements by experts on the training requirements for physicians involved with airway management in critically ill patients using a Delphi process.
Study: NCT06689436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 mg Apixaban Oral Dissolving Film (fasting)
Description: Single dose of 5 mg Apixaban Oral Dissolving Film will be administered orally after at least 10 hours overnight fast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 mg Apixaban Oral Dissolving Film (fed)
Description: Single dose of 5 mg Apixaban Oral Dissolving Film will be administered orally at 30 minutes after the start of a standardized high-fat, high-calorie breakfast that is preceded by at least 10 hours overnight fast

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5 mg Apixaban Oral Tablet (US RS/RLD)
Description: Single dose of 5 mg Apixaban Oral Tablet (US RS/RLD) will be administered orally after at least 10 hours overnight fast

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5 mg Apixaban Oral Tablet (EU product)
Description: Single dose of 5 mg Apixaban Oral Tablet (EU product) will be administered orally after at least 10 hours overnight fast
Study: NCT06691152

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19 Universal CAR-T cells
Description: Three dose groups (1×10\^7/kg, 3×10\^7/kg, 6×10\^7/kg) were set up, starting from the low dose group climbing to explore the safe and effective dose.
Study: NCT06689085

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate
Description: XYOSTED 50mg, XYOSTED 75 mg, XYOSTED 100 mg
Study: NCT06316063

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Apnoeic oxygenation with high-flow nasal oxygen
Description: The subjects in the intervention group will be oxygenated with HFNO during the surgical procedure.
Study: NCT06158100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax will be given orally (PO) at the assigned doses of 50 or 100 mg once daily for 7, 14 or 21 days starting at day 1 of each 28-day cycle, for up to 12 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine will be administered at a dose of 20mg/m\^2 once daily subcutaneously (SC) or intravenously (IV) for five days (Days 1-5) of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine will be administered at a dose of 20mg/m\^2 once daily subcutaneously (SC) or intravenously (IV) for five days (Days 1-5) of each 28-day cycle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Donor Lymphocyte Infusion
Description: Donor lymphocyte infusions (DLI) may be administered at the discretion of the treating physician, if certain criteria are met. Participants may receive up to three (3) infusions of donor lymphocytes (a type of white blood cell) at the following dose levels and study timepoints:~* DLI 1: 1x10\^6 cluster of differentiation 3+ (CD3+) cells/kg, after cycle 3~* DLI 2: 5x10\^6 CD3+ cells/kg, after cycle 5, if there is persistent MRD~* DLI 3: 1x10\^7 CD3+ cells/kg, after cycle 7, if there is persistent MRD.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Donor Lymphocyte Infusion
Description: Donor lymphocyte infusions (DLI) may be administered at the discretion of the treating physician, if certain criteria are met. Participants may receive up to three (3) infusions of donor lymphocytes (a type of white blood cell) at the following dose levels and study timepoints:~* DLI 1: 1x10\^6 cluster of differentiation 3+ (CD3+) cells/kg, after cycle 3~* DLI 2: 5x10\^6 CD3+ cells/kg, after cycle 5, if there is persistent MRD~* DLI 3: 1x10\^7 CD3+ cells/kg, after cycle 7, if there is persistent MRD.
Study: NCT06364774

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALS20
Description: novel lentiviral vector ALS20
Study: NCT06470672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1921
Description: Anti-TROP-2 ADC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: PD-L1 inhibitor
Study: NCT05158387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tozorakimab
Description: Administered subcutaneously tozorakimab Dose 1 and placebo through Week 52.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tozorakimab
Description: Administered subcutaneously tozorakimab Dose 2 through Week 52.
Study: NCT06316063

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical ventilation
Description: Study subjects in the comparator group will be tracheally intubated and mechanically ventilated
Study: NCT05182437

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: LINAC-based Stereotactic Radiotherapy
Description: Target definition: the target volume is defined as the epileptogenic zone (EZ) on all (non) invasive examinations (e.g. 3, 7 Tesla MRI or Stereo-EEG) of the presurgical path. Planning target volume (PTV) = GTV. A single fraction SRT with a prescribed isotoxic dose of 24 Gy to the 100% surrounding isodose. Dose is depending on the proximity and maximum tolerable dose to the radiosensitive organs at risk and EZ volume resulting in a V12\<= 10 cc reducing the risk on radionecrosis.

Intervention type: RADIATION
Group type: OTHER
Intervention: LINAC-based Stereotactic Radiotherapy
Description: Target definition: the target volume is defined as the epileptogenic zone (EZ) on all (non) invasive examinations (e.g. 3, 7 Tesla MRI or Stereo-EEG) of the presurgical path. Planning target volume (PTV) = GTV. A single fraction SRT with a prescribed isotoxic dose of 24 Gy to the 100% surrounding isodose. Dose is depending on the proximity and maximum tolerable dose to the radiosensitive organs at risk and EZ volume resulting in a V12\<= 10 cc reducing the risk on radionecrosis.
Study: NCT06131073

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: speed endurance production (SEP) training along with conventional training.
Description: this include speed endurance training for 3 days in a week for 8 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional training
Description: this include conventional training for 3 days in a week for 8 weeks.
Study: NCT05005208

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rehabilitation program with the support of the technological platform SI-ROBOTICS
Description: A 16-treatment session will be conducted, divided into 2 training sessions per week, for 8 weeks. The therapy sessions last 60 minutes; each session will involve 2 patients at time. Cardiac and respiratory activity monitoring is planned during robotic treatments in order to detect the heart rate during physical activity. Individual participants must complete at least 80% of the sessions. Recovery of 2 sessions will be possible.~Each session involves the following activities:~* Breathing, relaxation and postural harmonization exercises;~* Active mobility and stretching exercises;~* Irish dance with the SI-ROBOTICS system;~* Relaxation exercises.
Study: NCT05288985

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Erector spinae plane catheter group in addition to Systemic Analgesia
Description: Erector spinae plane catheter is placed in the post-interventional surveillance room in the operating theatre by an anaesthetist-intensive care physician or in the MIR department by the intensive care physician in charge of the patient within 2 hours after randomisation. The local anaesthetic injected into the catheter is Ropivacaine, prescribed according to a protocol of continuous flow, bolus and refractory period. The catheter is repositioned if a secondary displacement occurs.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Systemic Analgesia Only Group
Description: Systemic analgesia alone consists only of the 3 levels of analgesic treatment
Study: NCT05158387

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered subcutaneously, equivalent volume to tozorakimab through week 52.
Study: NCT05351294

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: All patients in Arm 2 will be seen and treated by one of three ROs with an interest in participating in this study, who will be trained by the PI to perform these visits reproducibly and with rigor. These will all be regular ROs, who like most ROs administer a mix of curative and PRT in their clinical practice; like most cancer centers, there are no ROs who formally subspecialize in PRT at our institution. Notably, patients in Arm 1 (control arm) will always have standard-of-care RO referral available for consideration of PRT if needed for symptom relief. However, patients in Arm 1 will be seen by other ROs without any specific training for this study. Any courses of PRT administered in either arm are at the discretion of the treating RO in terms of the timing, dose, fractionation, and treatment technique.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Early Radiation Oncology Involvement Alongside Standard Oncologic Care
Description: Early Radiation Oncology Involvement Alongside Standard Oncologic Care
Study: NCT05640102

Intervention type: DRUG
Intervention: Zanubrutinib
Description: Dosing and treatment duration are at the discretion of the prescribing physician and in accordance with local labeling

Intervention type: DRUG
Intervention: Zanubrutinib
Description: Dosing and treatment duration are at the discretion of the prescribing physician and in accordance with local labeling
Study: NCT05540639

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified Mindfetalness
Description: The pregnant woman is motivated to practice Mindfetalness verbally, by video, by a leaflet and at a website.
Study: NCT06553027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVN424 75 mg
Description: Participants will receive 75 mg CVN424 tablet once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVN424 150 mg
Description: Participants will receive 150 mg CVN424 tablet once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo tablet once daily.
Study: NCT05014490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exib 120 mg etoricoxib film-coated tablets
Description: Oral, COX-2 highly selective, non-steroidal anti-inflammatory generic drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arcoxia® 120 mg etoricoxib film-coated tablets
Description: Oral, COX-2 highly selective, non-steroidal anti-inflammatory innovative drug
Study: NCT05805202

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sampling and urine analysis
Description: A blood sample of 10- 20 ml from pediatric patients, 30-50 ml from adult patients will be collected for each patient and healthy voluntarees
Study: NCT06694519

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Sandvik's test
Description: It provides information on the severity of the UI by means of two questions. The interpretation based on the score is classified as: 1-2 mild UI, 3-6 moderate UI, 8-9 severe UI, 12 very severe UI.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Sandvik's test
Description: It provides information on the severity of the UI by means of two questions. The interpretation based on the score is classified as: 1-2 mild UI, 3-6 moderate UI, 8-9 severe UI, 12 very severe UI.